Oxford, UK – 6 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: Oxford Biomedica), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London. In accordance with Listing Rule 9.6.18, the following resolution was passed at the meeting:
Resolution 1: THAT, the entry by the Company into the proposed secured Loan Facility of up to £5 million with Vulpes Life Sciences Fund, being a related party transaction for the purposes of the Listing Rules, be and is hereby approved.
The full text of the Shareholder Circular and the Notice of Meeting can be viewed by visiting the Company’s website at www.oxfordbiomedica.co.uk.
Certified copies of the document setting out the above resolution passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.
The results of the proxy voting in advance of the meeting are shown below.
|
Resolution |
1 |
|---|---|
|
Votes for |
331,276,628 |
|
Votes at Chairman’s discretion |
1,016,145 |
|
Votes at other proxy discretion |
981,574 |
|
Votes against |
718,232 |
|
Votes withheld |
716,075 |
|
Total votes cast |
334,708,654 |
|
Result |
Approved |
-Ends